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Background: Whilst reports on the use of 1% voriconazole
eye drops in the management of ophthalmic fungal kerati-
tis have been promising, the voriconazole concentrations
achieved in the eye were not sufﬁciently high to treat all
types of fungal keratitis. Higher concentration of voricona-
zole eye drops may be required. We investigated the topical
application of 2% voriconazole solution for the management
of ophthalmic mycoses.
Methods: Voriconazole solution (2%) was prepared by
reconstituting intravenous Vfend® with sterile water pre-
served with 0.01% benzalkonium chloride. In a prospective
open label study, non-keratitis patients scheduled for elec-
tive anterior segment eye surgery were recruited to receive
2% voriconazole eye drops hourly, commencing 4 hours
before surgery. Aqueous humour samples were removed
during surgery and analysed by high-performance liquid
chromatography. 2% voriconazole eye drops were concur-
rently stored and monitored for stability.
Results: Fourteen patients participated in the study.
Eight samples were analysed (six samples were insufﬁcient
for analysis). The mean (± standard deviation) voriconazole
concentration was 1.51± 1.00g/mL, and the mean sam-
pling time after last-dose was 1.39 h. No side effects were
reported by patients. The eye drops demonstrated excel-
lent physical and chemical stability at refrigerated and room
temperatures for at least 4 months.
Conclusion: This is the ﬁrst study to report on the topi-
cal application of 2% voriconazole eye drops. The eye drops
appear to be safe, and the concentration of voriconazole
achieved is adequate to treat most common fungal kerati-
tis, and is similar to that reported in literature with the
1% solution administered with the same dosing frequency.
This suggests that the penetration of voriconazole into the
aqueous humour may not be concentration driven, at least
through the intact infection-free cornea.
doi:10.1016/j.ijid.2008.05.764
45.023
Effect of Dodonaea viscosa var. angustifolia on Candida
proteinase production and oral epithelial adherence from
HIV+ and HIV− patients
M. Patel
University of the Witwatersrand and National Health
Laboratory Services, Clinical Microbiology and Infectious
Diseases, Johannesburg, South Africa
Candida albicans isolated from HIV+ patients are known
to be more virulent than from HIV− patients. Critical steps
in oral Candidiasis pathogenisis is oral epithelial cells adher-
ence and proteinase production. The leaves of an indigenous
South African plant Dodonaea viscosa var. angustifolia are
used as a traditional remedy for treating Candidiasis. This
study investigated the effect of a crude extract of this plant
on C. albicans adherence and proteinase production which
were isolated from HIV+ and HIV− patients. Twenty isolates
from HIV+ and 20 from HIV− patients were used in the study.
Proteinase assay (P) and adherence test (A) was done on iso-
lates treated with plant extract (p) and water as a control
(c). For proteinase assay (mg/ml), quantitative spectropho-
tometric analysis was performed. For the adherence test,
Candida cells were treated with plant extract or water and
mixed with freshly isolated oral epithelial cells. The epithe-
lial cells were harvested, washed, slides were prepared
and stained. Adherent Candida cells per 100 epithelial cells
were measured for each test. In proteinase assay, results
were analysed using two-way ANOVA. In adherence test,
results were compared using t-test and the results of iso-
lates from HIV+ and HIV− patients were compared using
two-way ANOVA. Plant extract reduced the adherence of
Candida/100 epithelial cells (HIV+: Ac 316, Ap 203; HIV−: Ac
397, Ap 258) signiﬁcantly in both isolates (p < 0.001). How-
ever, there was no signiﬁcant difference between proteinase
production in isolates from HIV+ (Pp:2.0 and Pc:1.87mg/ml,
p < 0.05) and HIV− patients (Pp and Pc: 1.9mg/ml, p > 0.05).
In adherence test and proteinase assay, there was no dif-
ference in the results of the isolates from HIV+ and HIV−
patients. D. viscosa has ability to signiﬁcantly reduce Can-
dida adhesion to oral epithelial cells.
doi:10.1016/j.ijid.2008.05.765
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Opportunistic fungal infection is common in immunocom-
promised and immunosuppressed patients. Despite advances
in antifungal therapies, many problems remain to be solved
for most antifungal drugs available, for example, the use of
amphotericin B, also known as ‘‘gold standard’’, is limited
because of its infusion-related reactions and nephrotoxic-
ity. Another major problem in the clinical management of
patients with fungal infections is the development of drug
